Biocon Settled Patent Dispute Over Pebrilzo Biosimilar
The agreement clears a path for Biocon to launch its breast cancer treatment in the US, EU, and UK starting in 2027.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Do you believe patent settlements between drug manufacturers help patients gain access to affordable cancer treatments?
Biocon has secured a global settlement with Genentech to resolve all pending patent disputes regarding Pebrilzo, a biosimilar to the HER2-positive breast cancer drug Perjeta. The company plans to begin rolling out the treatment in international markets over the next two years.
Why it matters
The settlement removes legal barriers to commercialization, providing a defined timeline for Biocon to compete in the highly regulated oncology market. This agreement resolves the uncertainty surrounding intellectual property that previously hindered product distribution.
Biocon shares traded at 348.3 rupees on October 14, 2026, marking a 0.8% decline on the day of the announcement. This adds to a 10% decline in the company's share price year-to-date.
The players
Biocon
An international biopharmaceutical company specializing in the development of generic formulations, biosimilars, and novel biologics.
Genentech
A biotechnology firm and subsidiary of Roche that focuses on oncology, immunology, and tissue growth factors.
The details
Pebrilzo is a biosimilar—a biological medical product highly similar to an already approved reference product—developed to treat HER2-positive breast cancer. The drug targets the same protein as Genentech's reference product, Perjeta, which helps manage cancers that overexpress the human epidermal growth factor receptor 2. Through this settlement, the companies have resolved all active patent litigation, enabling the manufacturing and distribution of the biosimilar version in key global territories.
Timeline
October 14, 2026: Biocon announced the formal patent settlement agreement.
First quarter of 2027: Pebrilzo will launch in the European Union and UK.
Third quarter of 2028: Biocon is scheduled to launch Pebrilzo in the US.
2026-2028: Additional international market launches are planned.
The Tech Race
This settlement aligns Biocon with industry standards for resolving intellectual property conflicts regarding biosimilar drug development. It follows the established path for market entry relative to the Perjeta reference drug market authorization.
Patients and healthcare providers in the EU and UK can expect the availability of Pebrilzo starting in the first quarter of 2027. US clinicians and patients will gain access to the biosimilar treatment in the third quarter of 2028.
The takeaway
The settlement provides a clear timeline for the introduction of biosimilar alternatives to established oncology treatments. Observers should track the Q1 2027 launch in the EU and UK as a bellwether for the drug's commercial adoption.
Further reading
For more on the developments in the pharmaceutical industry, visit Biotech.
Live Poll
Do you believe patent settlements between drug manufacturers help patients gain access to affordable cancer treatments?
